25 September 2019 News
Bayer has committed more than $30m over the next five years to support research projects on therapies for chronic lung diseases at a joint lab in the US.
20 September 2019 Research Reports
Nursing home population in the 7MM, a high risk group for RSV infections, set to grow by 24% to 6.2m people by 2028, says GlobalData
Human Respiratory Syncytial Virus (RSV) is an enveloped, single-stranded, negative-sense RNA orthopneumovirus which belongs to the bigger family of Paramyxoviridae. This disease has only been public knowledge since 1956, when...
17 September 2019 Comment
There are at least 215 possible cases across 25 states where the development of severe lung disease has been linked to vaping.
13 September 2019 News
GlaxoSmithKline (GSK) has received the approval of the US Food and Drug Administration (FDA) for its Nucala (mepolizumab) drug to treat severe eosinophilic asthma in children aged 6-11 years.
12 September 2019 News
Vertex Pharmaceuticals has announced two of its cystic fibrosis (CF) drugs, Orkambi (lumacaftor-ivacaftor) and Symkevi (tezacaftor/ivacaftor) will now be available to eligible patients in Scotland through the National Health Service...
10 September 2019 News
The US Food and Drug Administration (FDA) has approved Boehringer Ingelheim’s Ofev (nintedanib) medicine to slow the rate of pulmonary function decline in systemic sclerosis-associated interstitial lung disease (SSc-ILD) patients.
29 August 2019
The US Centers for Disease Control and Prevention recently issued a press release reporting a rise in severe lung illness associated with e-cigarette use.
21 August 2019 Analysis
In response to failing negotiations between the UK’s National Health Service and Vertex over the CF drug Orkambi, parents of children with CF have created a buyers’ club to get...
30 July 2019 Analysis
The current standard of care for COPD is at least one or two bronchodilators, sometimes supplemented by an anti-inflammatory inhaled corticosteroid, however, two-thirds of patients on the maximum triple therapy...
26 July 2019 News
Venture capital firm Sofinnova Partners has dispossessed its portfolio company Breath Therapeutics to Italian pharmaceutical firm Zambon for a total consideration of up to $550m (€500m), including a €140m upfront...